Anar al contingut
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Tots els camps
Títol
Autor
Matèria
Signatura
ISBN/ISSN
Etiqueta
Trobar
Avançada
Ranibizumab versus Bevacizuma...
Citar
Enviar aquest missatge de text
Enviar per correu electrònic aquest
Imprimir
Exportar registre
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Enllaç permanent
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Dades bibliogràfiques
Autors principals:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Format:
Journal article
Publicat:
2012
Fons
Descripció
Ítems similars
Visualització del personal
Ítems similars
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
per: Chakravarthy, U, et al.
Publicat: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
per: Chakravarthy, U, et al.
Publicat: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
per: Dakin, H, et al.
Publicat: (2014)
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
per: Wen-Jie Wang, et al.
Publicat: (2015-02-01)
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
per: Zhe-Li Liu, et al.
Publicat: (2013-04-01)